HCPCS code J0256 – Alpha-1 proteinase inhibitor injection

Key takeaways

J0256 bills alpha-1 proteinase inhibitor (human), not otherwise specified, at one unit per 10 mg. It covers Prolastin-C, Prolastin-C Liquid, Aralast NP and Zemaira, while Glassia has its own code, J0257.

Units come from the weight-based dose. Multiply 60 mg/kg by the patient’s weight in kg, then divide by 10, because a unit error is a common cause of J0256 underpayment.

NDC is required on most payer claims for J0256, including Medicaid. Report it in 11-digit 5-4-2 format with qualifier N4.

Pabau, the practice management software we build, helps billing staff track J0256 claim status and documentation before submission.

HCPCS code J0256: Definition and code descriptor

HCPCS code J0256 is the Level II code for injection, alpha-1 proteinase inhibitor (human), not otherwise specified, 10 mg. CMS maintains it within the HCPCS Level II coding system, which covers drugs given by infusion or injection in outpatient and physician settings. The “not otherwise specified” wording is deliberate. J0256 is the catch-all code for A1PI products that have no product-specific HCPCS code of their own.

The unit of service is 10 mg. A patient receiving a 4,200 mg infusion would be billed at 420 units. The division is simple. The harder step sits upstream, because the administered dose depends on the patient’s weight.

Which drugs does J0256 cover?

J0256 covers the FDA-approved alpha-1 proteinase inhibitor (human) products that have no product-specific HCPCS code. The products billed under J0256 are Prolastin-C and Prolastin-C Liquid (Grifols), Aralast NP (Takeda), and Zemaira (CSL Behring). The NDC on the claim identifies which product was administered, so accurate NDC selection matters for audit compliance.

Glassia (Kamada/Takeda) is the exception. It has its own code, J0257, so a Glassia infusion never bills under J0256. The other products would move off J0256 only if CMS assigns one of them a product-specific code, so check each quarterly HCPCS update.

J0256 unit billing: How to calculate and report units

J0256 is billed per 10 mg of alpha-1 proteinase inhibitor administered. Dosing is weight-based, so the billable unit count comes from the administered dose and never from a fixed vial size. Coder forums often cite unit errors as a common cause of J0256 underpayment and overpayment audit flags.

The standard clinical dose for AATD augmentation therapy is 60 mg/kg per week, administered intravenously. Use this formula to convert a dose to billable units, then compare the result with the two common decimal errors shown below the table.

Round down to the nearest whole unit only if the administered dose does not reach the next 10 mg threshold. Never bill vial waste as administered dose. Some payers allow billing for the full vial when the remaining product cannot be reused. That requires the single-use policy and the waste to be documented in the medical record.

NDC code requirement for J0256 claims

An NDC is mandatory on J0256 claims for Medicaid (under the Deficit Reduction Act drug rebate rules) and for most commercial payers. Medicare typically does not require it on professional J-code claims. At payers that do require it, a missing or malformatted NDC is a frequent cause of automatic J0256 denial.

Without the NDC, the payer cannot confirm which A1PI product was administered. Clean claim submission needs the NDC present, correctly formatted, and matched to the product named on the prior authorization.

The NDC must be reported in 11-digit 5-4-2 format (XXXXX-XXXX-XX). On the CMS-1500 paper form, it goes in the shaded area of box 24A, with qualifier N4 before the 11 digits. On the 837P electronic transaction, it appears in loop 2410, segment LIN, with qualifier N4 in element LIN02 and the NDC in element LIN03.

• Source the NDC from the label of the vial administered, never from memory or a formulary reference. NDCs differ by vial size and package, even within one brand.
• Verify the 11-digit format. FDA NDC directories list codes in 10-digit format. Add a leading zero to the appropriate segment to reach 11 digits (5-4-2). Which segment receives the leading zero depends on the original FDA labeler format.
• Record the NDC in the chart at the time of administration, along with the lot number and expiration date. Payers may request this documentation during post-payment audit.
• Match the NDC to the brand on the PA. If the authorization names Prolastin-C and Zemaira was given instead, update the PA before billing. Submitting an NDC that does not match the authorized product triggers denial.

ICD-10-CM diagnosis codes that support J0256

Payers require a covered ICD-10-CM diagnosis code on the J0256 claim to establish medical necessity. E88.01 (alpha-1 antitrypsin deficiency) is the primary diagnosis code and is accepted by Medicare, Medicaid, and virtually all commercial payers that cover A1PI therapy. Claims submitted without E88.01 or with an unsupported secondary diagnosis are automatically denied for non-covered indication.

Confirm the diagnosis code requirements against the applicable Local Coverage Determination (LCD) for A1PI therapy before submission. LCD criteria list the accepted ICD-10-CM codes, the minimum documented serum A1AT level, and the required pulmonary function test findings.

Prior authorization requirements for J0256

Prior authorization is required by nearly all commercial payers for J0256 and must be obtained before the first infusion, not after. Medicare Part B does not require PA for J0256. It enforces coverage criteria through the applicable LCDs instead, which work as its medical necessity review. Running insurance eligibility verification before the first infusion is scheduled prevents denials that cannot be corrected later.

Commercial payer PA packages for J0256 typically require these four items:

• The laboratory report confirming a serum A1AT level below the coverage threshold, typically under 11 microM or 57 mg/dL (thresholds vary by payer)
• Spirometry or full PFTs documenting obstruction
• The prescribing pulmonologist’s NPI and specialty
• The specific product and the planned weekly dose

Anthem has published a medical policy for A1PI augmentation therapy. Check the current policy’s effective date when you submit PA documentation, because the criteria are updated periodically.

Medicare and Medicaid coverage for J0256

Medicare Part B covers J0256 as a physician-administered drug under the buy-and-bill model. The practice buys the drug, administers it, and bills Medicare for both the drug and the administration. Reimbursement follows the Average Sales Price (ASP) methodology at ASP plus 6%, which CMS publishes quarterly.

For current rates, check the CMS Physician Fee Schedule lookup tool or the quarterly ASP drug pricing file. Dollar figures change every quarter, so this guide quotes none.

Coverage under Medicare is subject to the applicable Local Coverage Determination for alpha-1 antitrypsin products. The LCD sets the clinical eligibility criteria. They include a minimum documented serum A1AT level, baseline FEV1 as a percentage of predicted, and smoking history requirements. Patients with emphysema too severe to benefit are excluded.

Claims that miss the LCD criteria are denied as not medically necessary, even when no PA was required. Pabau’s claims management software helps billing staff track claim status and documentation before submission.

Home infusion of A1PI drugs may require a different billing pathway. When a specialty pharmacy supplies the drug for home infusion, the J0256 drug claim may shift away from the prescribing practice. The pharmacy or home infusion provider may bill it instead. Confirm the site-of-service billing pathway with your compliance counsel before billing J0256 for home-administered doses.

How to bill J0256 with infusion administration codes

J0256 covers the drug only. When a nurse or physician gives the infusion in an office or outpatient setting, the practice also bills an administration code. That is usually 96365 for the first hour. A missing or wrongly bundled administration line gets that part of the encounter denied.

The superbill documentation for a J0256 infusion records the start and stop times, the dose in mg, the lot number, and the NDC. It also names the administering provider. The infusion times support the administration code. The dose supports the unit count on the drug line.

Codes that are commonly confused with J0256

J0256 is the “not otherwise specified” code for the A1PI drug class. Glassia is already billed under its own code, J0257, and reporting it as J0256 is incorrect coding that may trigger recoupment. Prolastin-C, Prolastin-C Liquid, Aralast NP and Zemaira stay on J0256 unless CMS assigns one of them a product-specific code.

Verify the HCPCS code status of each A1PI product at the start of every year. Use the AAPC HCPCS code lookup or the CMS annual HCPCS update files.

The most common substitution error is a swap between J0256 and J0257. J0257 covers Glassia only, and Glassia is given intravenously like the products billed under J0256. No subcutaneous A1PI product is approved in the US, so the product on the vial label decides the code.

Common J0256 claim denial reasons and how to fix them

J0256 claims carry more denial risk than most drug claims. They combine weight-based dosing, NDC reporting, near-universal commercial PA, and LCD-governed medical necessity. Good denial management workflows for infusion practices check each of these points before the claim is sent. Reading the claim denial codes on each remittance advice shows which point keeps failing.

Documentation checklist for J0256 claims

Use the two lists below as a pre-submission check for every J0256 encounter. The first covers the chart, and the second covers the claim itself. Applying medical billing compliance checks at this stage prevents the rework cycle that follows a denial.

In the medical record (chart requirements):

• Confirmed AATD diagnosis with documented serum A1AT level and date of laboratory result
• Pulmonary function test results (FEV1 % predicted, FVC, FEV1/FVC ratio) supporting medical necessity per applicable LCD
• Prescribing physician’s NPI, specialty, and signature on the treatment order
• Administered dose in mg, calculated from patient weight documented at the visit (or most recent verified weight)
• Product name (brand), lot number, and expiration date from the administered vial
• NDC from the vial label (11-digit, 5-4-2 format)
• Infusion start and stop time (required to support 96365 / 96366 administration codes)
• Waste documentation if full vial was opened and partial volume was not administered
• PA approval number and effective dates (commercial payers)

On the claim (billing requirements):

• HCPCS code J0256 with the correct unit count (administered mg divided by 10, rounded down)
• NDC in 11-digit format with qualifier N4 (box 24A on CMS-1500; loop 2410 on 837P)
• ICD-10-CM E88.01 as the primary diagnosis code
• Companion administration code (96365 and/or 96366) with documented infusion time
• Place of service code (11 for office, 22 for hospital outpatient, etc.)
• PA authorization number in field 23 of the CMS-1500 (commercial payers)
• Rendering provider NPI and prescribing provider NPI (where required by payer)

How Pabau keeps J0256 claims complete before submission

On a typical infusion day, the dose, the vial’s NDC and the infusion times go into the chart. Someone else then keys them into the claim. Each handoff is a chance for 420 units to become 42, or for the NDC to drop off the drug line.

Pabau runs clinical notes, forms and insurance billing in one system. The dose and infusion times recorded at the chair sit in the same patient record the claim is built from. Billing staff can then track each claim’s status and documentation before it is submitted.

The result is fewer corrected claims, and less time spent chasing a payer over a J0256 line that should have paid the first time.

Track J0256 claims from code to payment

Pabau’s claims management software helps infusion practices track claim status and documentation before submission, so J0256 claims reach the payer complete.

Book a demo

Conclusion

J0256 claims are decided at the infusion chair. When the dose, the NDC and the infusion times are recorded as the drug goes in, nobody has to rebuild the claim from memory later.

If you add one check first, make it the unit cross-check against the administered dose. A slipped decimal costs the most and is the easiest error to catch. Then confirm the product on the vial, because a Glassia vial moves the claim to J0257.

Book a demo to see how Pabau helps infusion practices track J0256 claim status and documentation before submission.

Continue your research

Need a framework for managing infusion drug denials? Denial management in healthcare covers the end-to-end workflow for identifying, appealing, and preventing recurring claim denials.

Want to understand how drug claims move through the clearinghouse? 837 file guide explains the electronic claim transaction format, including how NDC loop 2410 is structured for drug codes.

Looking for a complete overview of medical billing requirements? What is revenue cycle management covers the full claim lifecycle from patient registration through payment posting.

New to drug and administration billing? What is medical billing walks through how codes, claims and payments fit together for a practice.

Frequently asked questions